PubMed Health⌕ Search

Biomedical subjects

Elizaveta Chabanova

Publications and source records attributed to Elizaveta Chabanova.

9 recordsLinked to original sources
PubMed2006

Initial clinical experience with oral manganese (CMC-001) for liver MR imaging.

Recently, a new oral liver-specific manganese-based MR agent (CMC-001) has been introduced. This contrast medium is delivered to the liver in high concentrations in the portal vein and very low doses in the hepatic artery, as only small amounts of manganese enter the general circulation. It is taken up by the hepatocytes and excreted in the bile. Our initial experience with the new MR contrast medium in a variety of patients is reported. A total of 20 patients (11 males and 9 females) were studied with MR imaging 2 h after oral ingestion of the contrast agent. Sixteen patients were referred for evaluation of focal liver lesion(s), whereas in the remaining four patients, evaluation of the biliary tract was requested. In the 17 patients without biliary obstruction, there was an increased signal intensity of the liver parenchyma, whereas in the three patients with biliary obstruction, the uptake was delayed. There was excellent visualization of the biliary system on the T1-weighted images in the 16 patients without biliary obstruction referred for evaluation of a focal liver lesion. In seven patients, the uptake was patchy. In patients with focal liver lesions or biliary tract diseases, it is possible to increase the signal intensity of the liver parenchyma after the oral intake of CMC-001. In patients without biliary tract obstruction, the biliary system is easily visualized. Oral manganese seems to be useful in hepatobiliary MRI. Further research is strongly warranted.

Adult↗
PubMed2006

Imaging liver metastases with a new oral manganese-based contrast agent.

RATIONALE AND OBJECTIVES: The purpose of the study was a preliminary evaluation of a new oral, manganese-based, liver-specific contrast medium (CMC-001; CMC Contrast AB, Malmoe, Sweden) for magnetic resonance imaging (MRI) in patients with liver metastases. MATERIALS AND METHODS: The study included 10 consecutive patients with known liver metastases. Patients underwent abdominal MRI as a supplement to routine diagnostics. Patients fasted for at least 10 hours before ingesting CMC-001 (1.6 g manganese chloride tetrahydrate, 1 g alanine, and 1,600 IU vitamin D3 were dissolved in water). MRI took place before and 2 hours after drinking CMC-001. The 1.5-T MRI protocol included two-dimensional T1w sequences to visualize metastases. T2w and diffusion weighted imaging (DWI) sequences were used to identify cysts and blood vessels correspondingly. RESULTS: The intake of CMC-001 caused an increase in the signal intensity of the "healthy" liver tissue, making the internal structure of the liver significantly better visualized. Compared with our routine examinations, MRI showed more metastases in four patients and allowed determining a more precise outline of metastases. CONCLUSION: CMC-001 improves imaging of liver metastases in comparison with computed tomography and with MRI without CMC-001.

Administration, Oral↗
PubMed2005

[Magnetic resonance colonography: a new diagnostic tool].

Magnetic resonance colonography (MR colonography) is a three-dimensional imaging of the colon. Data postprocessing also allows for virtual colonoscopy, depicting the intraluminal morphology. Acquisition and postprocessing of high-resolution images require a state-of the-art modern MR scanner and a workstation. Regarding patient preparation, a bowel cleansing is necessary. The results of cancer screening have shown MR colonography to be superior to the traditional double-contrast barium enema. In inflammatory bowel disease, MR colonography can be used to assess disease activity, including spreading.

Colonic Neoplasms↗
PubMed2005

Preliminary experience with contrast-enhanced MR angiography in patients with end-stage renal failure.

RATIONALE AND OBJECTIVES: The purpose of this study was to evaluate our preliminary experience with routine contrast-enhanced magnetic resonance angiography (CE-MRA) of the lower limb arteries in patients with end-stage renal failure. MATERIALS AND METHODS: A retrospective analysis was performed on clinical, physiological, and imaging data for 104 patients with end-stage renal failure. Patients were considered to be in end-stage renal failure if they were on renal replacement therapy (peritoneal or hemodialysis) or were being evaluated as part of a pretransplant workup. CE-MRA was carried out on a 1.5-T scanner using a single-injection, three-station moving table technique. RESULTS: Eleven percent of asymptomatic patients with normal ankle/brachial pressure indexes (ABPI) were found to have severe arterial disease on CE-MRA, and in 30% of asymptomatic patients with abnormal ABPI, CE-MRA showed mild or no disease. Moreover two of three symptomatic patients with normal ABPI were shown to have severe disease. Two patients on peritoneal dialysis had to be switched to hemodialysis. No other adverse events were revealed. CONCLUSION: CE-MRA is a useful adjunct to clinical and physiological examination for the evaluation of the lower limb arteries in a group of patients who have a higher-than-average incidence of peripheral vascular disease, yet have previously been severely restricted from traditional angiography because of contrast-medium-induced nephrotoxicity.

Adult↗
PubMed2004

Oral manganese for liver imaging at three different field strengths.

RATIONALE AND OBJECTIVES: To study the magnetic resonance imaging signal intensity of the liver and gall bladder before and after ingestion of a new oral manganese containing contrast medium at three different field strengths. MATERIALS AND METHODS: Twelve healthy male volunteers (mean age, 24.9 years; range, 20-39 years) underwent abdominal magnetic resonance imaging (T(2)W COR, T(1)W COR, T(1)W TRA) at 0.23 T, 0.6 T, and 1.5 T before and after the contrast administration. The duration of fasting was identical before the two studies. Volunteers were randomized into two equal groups (n = 6) to ingest either half or full strength CMC-001 providing either 0.8 or 1.6.g MnCl(2) plus absorption promoters. The CMC-001 dose was dissolved in 400 mL water and ingested 2.5 hours before imaging. The resulting images were evaluated with regard to visualization of the liver and the gall bladder by three radiologists. The signal intensity of the liver was also measured. Blood and urine samples were collected before and after ingestion of CMC-001. RESULTS: The intake of CMC-001 caused a significant increase in the signal intensity of the liver at all three field strengths and at both dosages (up to 90%) on the T(1)W images. The internal structure of the liver was significantly better delineated. The bile in gall bladder was bright after ingestion of the low dose, but dark after the full dose. On the T(2)W images, CMC-001 lowered the signal intensity of liver with up to 30%. CMC-001 had a slight metallic taste, but of no importance according to the volunteers. No systematic adverse reactions caused by the contrast medium were registered. No changes in the blood levels of various routine parameters were measured. CONCLUSION: It is possible to increase the signal intensity of the liver significantly by oral intake of essential nutritional elements including manganese. The imaging window is more than 2 hours.

Administration, Oral↗